Interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 in rats: Open-field revisited

Pharmacology Biochemistry and Behavior

Volumn 73, Issue 4, 2002, Pages 911-919

  Järbe, Torbjörn U C ^a   Andrzejewski, Matthew E ^a   DiPatrizio, Nicholas V ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

9 THC; Cannabinoid agonist; Cannabinoid antagonist; Open field; Rats; SR 141716

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GROOMING; LATENT PERIOD; MALE; MICTURITION; MOBILIZATION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SCRATCHING; VOCALIZATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; MALE; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

ANIMALIA;

EID: 0036830337     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00938-3     Document Type: Article

References (44)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 37:1994;1889-1893.
2. Arévalo C., de Miguel R., Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol, Biochem Behav. 70:2001;123-131.
3. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 60:2001;155-163.
4. Chaperon F., Thiébot M-H Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol. 13:1999;243-281.
5. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther. 277:1996;586-594.
6. Costa B., Colleoni M. SR141716 induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol Sin. 20:1999;1103-1108.
7. Costa B., Vailati S., Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol. 10:1999;327-331.
8. Darmani N.A. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol, Biochem Behav. 69:2001;239-249.
9. Darmani N.A. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55,212-2. Eur J Pharmacol. 430:2001;49-58.
10. Darmani N.A., Pandya D.K. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naïve mice. J Neural Transm. 107:2000;931-945.
11. Devane W.A., Hanûs L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
12. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulary action. Trends Neurosci. 21:1998;521-528.
13. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem. 75:2000;2434-2444.
14. 9-THC on the open-field activity of the rat. Psychopharmacologia (Berlin). 23:1972;289-299.
15. Ferrari F., Ottani A., Giuliani D. Cannabinoid activity in rats and pigeons of HU 210, a potent anti-emetic drug. Pharmacol, Biochem Behav. 62:1999;75-80.
16. Gallate J.E., McGregor I.S. The motivation for beer in rats: effects of ritansirin, naloxone and SR 141716. Psychopharmacology. 142:1999;302-308.
17. Henriksson B.G., Järbe T. Cannabis-induced vocalization in the rat. J Pharm Pharmacol. 23:1972;457-458.
18. Hiltunen A.J., Järbe T.U.C., Wängdahl K. Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. Pharmacol, Biochem Behav. 30:1988;675-678.
19. Howlett A.C. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol. 35:1995;607-634.
20. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., Frank R.A. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 58:2001;322-328.
21. Izzo A.A., Mascolo N., Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol. 11:2001;597-603.
22. 9-THC and other cannabinoids. Pharmacol, Biochem Behav. 71:2002;155-162.
23. Järbe T.U.C., Henriksson B.G. Vocalization: a characteristic cannabis-induced behavior in the rat? Physiol Psychol. 1:1973;351-354.
24. Järbe T.U.C., Hiltunen A.J. Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacology. 26:1987;219-228.
25. Järbe T.U.C., Hiltunen A.J., Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther. 250:1989;1000-1005.
26. Järbe T.U.C., Sheppard R., Lamb R.J., Makriyannis A., Lin S., Goutopoulos A. Effects of delta-9-THC and (R)-methanandamide on open-field behaviors in rats. Behav Pharmacol. 9:1998;169-174.
27. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology. 156:2001;369-380.
28. Kirk R.E. Experimental design: procedures for the behavioral sciences. 1968;Brooks/Cole, Belmont (CA).
29. 9-tetrahydrocannabinol dosing. Eur J Pharmacol. 398:2000;251-258.
30. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:1999;573-595.
31. Masserano J.M., Karoum F., Wyatt R.J. SR 141716A, a cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol. 10:1999;429-432.
32. Mechoulam R., Lander N., Feigenbaum J.J., Segal M., Järbe T.U.C., Hiltunen A.J., Consroe P. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 44:1988;762-764.
33. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur J Pharmacol. 359:1998;1-18.
34. Monory K., Tzavara E.T., Lexime J., Ledent C., Parmentier M., Borsodi A., Hanoune J. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun. 292:2002;231-235.
35. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1994;61-65.
36. Navarro M., Herandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., Rodriguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport. 8:1997;491-496.
37. Palmer S.L., Khanolkar A.D., Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr Pharmacol Design. 6:2000;1381-1397.
38. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 6:1999;635-664.
39. Pertwee R.G. Cannabinoids and the gastrointestinal tract. Gut. 48:2001;859-867.
40. Pertwee R.G., Coutts A., Griffin G., Fernando S.R., McCallion D., Stevenson L.A. The presence of cannabinoid CB1 receptors of prejunctional neurones of certain isolated tissue preparations: a brief review. Med Sci Monit. 2:1996;840-848.
41. Poncelat M., Barnouin M.C., Breliére J.C., Le Fur G., Soubrié P. Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology. 144:1999;144-150.
42. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Breliére J.C., LeFur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
43. Schlicker E., Kathman M. Modulation of transmitter release via presynaptic cannabinoid receptor. Trends Pharmacol Sci. 22:2001;565-572.
44. Sjödén P.O., Järbe T.U.C., Henriksson B.G. Effects of long-term administration and withdrawal of tetrahydrocannabinols (delta-8-THC and delta-9-THC) on open-field behavior in rats. Pharmacol, Biochem Behav. 1:1973;243-249.